UF researchers test stem cell therapy for heart patientsOctober 05, 2007
UF researchers plan to test the experimental therapy in people with severe coronary artery disease and daily chest pain who have not responded to traditional medications or surgical procedures designed to restore blood flow, such as angioplasty or bypass surgery.
"The general idea is that by providing these cells of blood vessel origin, we hope to either generate new blood vessels from the growth of these implanted cells or stimulate the heart to regenerate new blood vessels from the cells that reside in it," said study investigator Carl J. Pepine, M.D., chief of cardiovascular medicine at UF's College of Medicine. "It's not completely clear whether it's the actual cell itself that would do this or whether it's just the milieu and the chemical signals that occur from the cells that would result in this."
Each year, nearly half a million Americans with heart disease experience severe chest pain because coronary arteries and the smaller vessels that supply oxygen-rich blood to the heart muscle become narrowed or blocked by plaque deposits or clots. These blockages can trigger mini-heart attacks that, while too small to be noticed as they occur, over time irreversibly damage the heart - leading to disability, progressive heart failure or even death.
In the prospective, double-blind, placebo-controlled study, known as the Autologous Cellular Therapy CD34-Chronic Myocardial Ischemia Trial, or ACT34-CMI, UF researchers will study 15 Shands at UF medical center patients to determine whether a person's own stem cells can be used to effectively and safely treat chronic reductions in blood flow to the heart, improving symptoms and long-term outcomes. They also will evaluate whether participants report improved quality of life and exercise tolerance, and whether the heart functions better.
Participants will undergo screening tests and then receive a series of injections of a protein that releases stem cells from the bone marrow into the bloodstream. The cells, known as CD34+ stem cells, help spur blood vessel growth and are harvested from the patient during a procedure called apheresis, said Chris Cogle, an assistant professor of medicine at the UF's College of Medicine Program in Stem Cell Biology and Regenerative Medicine.
Participants will then be randomly assigned to receive one of two dosing levels of the cells, or a placebo.
"Physicians will use a catheter-based electrical mapping system to find muscle they think is still viable but not functioning," said R. David Anderson, an associate professor of medicine at UF and director of interventional cardiology. "The cells are injected into viable sites in the heart, which have poor blood flow, in the cardiac catheterization laboratory at Shands at UF medical center."
Patients will be periodically evaluated by echocardiography and magnetic resonance imaging over the course of a year after the procedure. Although to date study subjects have tolerated this procedure well, potential risks include infection, allergic reactions, bleeding, blood clots and damage to the heart or its vessels.
UF is one of 20 research sites participating in the national study, which is evaluating a total of 150 patients and is sponsored by the Cellular Therapies business unit of Baxter Healthcare Corp. and led by principal investigator Douglas Losordo, M.D., of Northwestern University's Feinberg School of Medicine. Baxter makes the cell-sorting equipment used to isolate the cells from the blood.
Pending Food and Drug Administration approval, UF researchers, through the National Heart, Lung and Blood Institute-funded Cardiovascular Cell Therapy Research Network, are gearing up to launch three other multicenter studies within the next several months that use other types of a patient's own stem cells.
One trial focuses on patients who have had a heart attack within a week preceding study enrollment, another focuses on patients whose heart attack occurred within the preceding two to three weeks, and the third focuses on patients with congestive heart failure or chronic chest pain that has not responded to traditional treatment.
These studies will use stem cells taken directly from the patients' bone marrow instead of stem cells isolated from the bloodstream, Pepine said, and will test whether various cell therapies can improve the heart's plumbing by helping to repair blood vessels or form new ones and strengthen the heart muscle to improve its ability to pump efficiently.
Douglas E. Vaughan, M.D., chief of the division of cardiovascular medicine at Vanderbilt University Medical Center, said the study is important and targets a challenging group of patients who need new options.
"There's a lot of enthusiasm in the cardiovascular community about the potential of cell-based therapies for the treatment of cardiovascular diseases," Vaughan said, "and there is increasing experience around the world in using bone marrow-derived stem cells in patients with cardiovascular disease. There is growing confidence this is going to be a safe form of therapy, but there are continuing questions about how effective it will be and what its impact will be in individual patients."
University of Florida
Related Stem Cells Current Events and Stem Cells News Articles
Blood to feeling: McMaster scientists turn blood into neural cells
Scientists at McMaster University have discovered how to make adult sensory neurons from human patients simply by having them roll up their sleeve and providing a blood sample.
Human stem cell model reveals molecular cues critical to neurovascular unit formation
Crucial bodily functions we depend on but don't consciously think about -- things like heart rate, blood flow, breathing and digestion -- are regulated by the neurovascular unit.
New techniques for reprogramming stem cells target neurological disease models
As scientists overcome the technical challenges in reprogramming stem cells to produce biologically precise models of human neurons, these emerging model systems will accelerate research on understanding neuronal activity, brain development, and neurological diseases, and will drive the discovery of new patient-specific, reprogramming-based therapies.
Printing 3-D graphene structures for tissue engineering
Ever since single-layer graphene burst onto the science scene in 2004, the possibilities for the promising material have seemed nearly endless.
Lung cell phenotype reverts when seeded onto decellularized lung matrix
Researchers seeded type II lung epithelial cells into a decellularized lung matrix to study their function and report the unexpected finding that instead of differentiating into type I lung cells, they instead transitioned to become mesenchymal cells, as would occur in wound healing.
Researchers make progress engineering digestive system tissues
New proof-of-concept research at Wake Forest Institute for Regenerative Medicine suggests the potential for engineering replacement intestine tissue in the lab, a treatment that could be applied to infants born with a short bowel and adults having large pieces of gut removed due to cancer or inflammatory bowel disease.
Research community comes together to provide new 'gold standard' for genomic data analysis
Cancer research leaders at the Ontario Institute for Cancer Research, Oregon Health & Science University, Sage Bionetworks, the distributed DREAM (Dialog for Reverse Engineering Assessment and Methods) community and The University of California Santa Cruz published the first findings of the ICGC-TCGA-DREAM Somatic Mutation Calling (SMC) Challenge (The Challenge: https://www.synapse.org/#!Synapse:syn312572) today in the journal Nature Methods.
Signaling pathway revealed through which a promising anti-leukemia drug kills cancer cells
Inhibiting a protein called BRD4 critical to the survival of acute myeloid leukemia (AML) cells has shown to be an effective therapeutic strategy.
Epilepsy has been found to reduce the generation of new neurons
The mission of neural stem cells located in the hippocampus, one of the main regions of the brain, is to generate new neurons during the adult life of mammals, including human beings, of course, and their function is to participate in certain types of learning and responses to anxiety and stress.
New age of genome editing could lead to cure for sickle cell anemia
UNSW Australia researchers have shown that changing just a single letter of the DNA of human red blood cells in the laboratory increases their production of oxygen-carrying haemoglobin - a world-first advance that could lead to a cure for sickle cell anaemia and other blood disorders.
More Stem Cells Current Events and Stem Cells News Articles